STAT3 and B-cell non-Hodgkin lymphoma: QCT has been reported to antagonize STAT3 signaling in B-cell lymphoma and breast cancer cells (Li et al., 2014; Seo et al., 2016) and down-regulate IL-6/STAT3 signaling in lung cancer cells (Mukherjee and Khuda-Bukhsh, 2015).